Information Provided By: 
Fly News Breaks for June 23, 2015
MDVN
Jun 23, 2015 | 08:03 EDT
UBS noted Medivation shares have been weak since ASCO but believes the risk reward has been skewed to the upside. The firm said its thesis is different from consensus as they believe the company's pipeline advancement this year could drive multiple expansion if Xtandi sales can at least remain flat. UBS reiterated its Buy rating and $142 price target on Medivation shares.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
